Embecta(EMBC)
PARSIPPANY, NJBiotechnology
Focus: Embecta is a publicly traded diabetes care company focused on insulin delivery devices and automated insulin delivery systems for metabolic diseases. With $1.1B in annual revenue and a profitable operating model, it operates as a specialized player in the diabetes technology segment.
Profile data last refreshed 8h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Embecta
AI assessmentNot HiringNo open roles listed right now. Follow Embecta to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$1.1B
Pipeline & Clinical Trials
An AID System.
Type 2 DiabetesClinical Trials (1)
NCT06692153Embecta AID System in Adults With Type 2 Diabetes
N/AHelp build intelligence for Embecta
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.